...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>World Journal of Oncology >Pazopanib-Induced Regression of Brain Metastasis After Whole Brain Palliative Radiotherapy in Metastatic Renal Cell Cancer Progressing on First-Line Sunitinib: A Case Report
【24h】

Pazopanib-Induced Regression of Brain Metastasis After Whole Brain Palliative Radiotherapy in Metastatic Renal Cell Cancer Progressing on First-Line Sunitinib: A Case Report

机译：一线舒尼替尼进展性全肾姑息放疗治疗转移性肾细胞癌后帕唑帕尼诱导的脑转移退化：一例报告

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Pervious randomized studies have demonstrated survival benefit in favor of tyrosine kinase inhibitors (TKIs) compared to cytokines in metastatic clear cell renal cell carcinoma (RCC). However, the role of TKIs for treating brain metastasis from RCC remains unknown. Previous studies have reported possible activity of sunitinib and sorafenib in RCC patients with brain metastasis. We report on patient with metastatic RCC who responded to first-line sunitinib but then progressed with multiple brain metastasis, but with controlled extra-cranial metastatic disease. The patient was treated with whole-brain palliative radiotherapy followed by treatment schedule of pazopanib at standard dose of 800 mg/day which was associated with a response in brain metastasis. Subsequently, she was re-challenged at reduced dose of 600 mg/day and developed further response in metastatic brain lesions. She lived for more than 3 years from initial diagnosis of brain metastasis. This is the first case report of sequential TKI therapy for treating metastatic RCC with brain metastasis and supports the probable use of pazopanib as potent TKI for treating patients with cerebral metastasis.World J Oncol. 2014;5(5-6):223-227doi: http://dx.doi.org/10.14740/wjon843w
机译：以往的随机研究表明，与转移性透明细胞肾细胞癌（RCC）中的细胞因子相比，酪氨酸激酶抑制剂（TKIs）具有生存优势。然而，TKIs在治疗RCC的脑转移中的作用仍然未知。先前的研究报道舒尼替尼和索拉非尼在患有脑转移的RCC患者中可能具有活性。我们报道了对一线舒尼替尼有反应的转移性RCC患者，但随后进展为多发性脑转移，但颅外转移性疾病得到了控制。患者接受全脑姑息放疗，随后以标准剂量800毫克/天的帕唑帕尼治疗方案接受治疗，这与脑转移反应有关。随后，她以600毫克/天的减量剂量再次受到挑战，并在转移性脑病变中进一步发展。从最初诊断为脑转移开始，她已经生活了3年以上。这是序贯TKI治疗治疗转移性RCC并伴有脑转移的RCC的第一例报道，并支持帕唑帕尼可能作为有效的TKI治疗脑转移患者。WorldJ Oncol。 2014; 5（5-6）：223-227doi：http：//dx.doi.org/10.14740/wjon843w

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号